AtriCure, Inc.
No enriched coverage for $ATRC in the last 7 days.
No SEC Form 4 filings for $ATRC in the last 30 days.
See all $ATRC insider activity →Citizens maintained a Market Outperform rating on AtriCure with a $68 price target, implying 17.9% upside from the Oct 20 close. The firm cited strong clinical trial progress and robust revenue growth outlook as key reasons, highlighting potential market expansion and financial improvements.
BlackRock reported a 15.4% ownership stake in AtriCure (ATRC), with sole voting and dispositive power over 7.8 million shares. The report also noted that iShares Core S&P Small-Cap ETF has an interest in more than 5% of AtriCure's outstanding common stock.
Analysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
Recent ATRC coverage spans financial news, market movers and insider activity.
Citizens maintained a Market Outperform rating on AtriCure with a $68 price target, implying 17.9% upside from the Oct 20 close. The firm cited strong clinical trial progress and robust revenue growth outlook as key reasons, highlighting potential market expansion and financial improvements.
The large BlackRock stake may be interpreted as a vote of confidence, potentially supporting the stock.
Mixed signal; higher target but rating downgrade.
Hold rating with higher target may be neutral to slightly positive.
The downgrade to Hold may trigger short‑term selling pressure despite the modest upside implied by the new target.
AlphAI scores every news story that mentions ATRC with an AI model for sentiment and relevance, and aggregates insider trades from AtriCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Citizens maintained a Market Outperform rating on AtriCure with a $68 price target, implying 17.9% upside from the Oct 20 close. The firm cited strong clinical trial progress and robust revenue growth outlook as key reasons, highlighting potential market expansion and financial improvements.
1 min readBlackRock reported a 15.4% ownership stake in AtriCure (ATRC), with sole voting and dispositive power over 7.8 million shares. The report also noted that iShares Core S&P Small-Cap ETF has an interest in more than 5% of AtriCure's outstanding common stock.
1 min readAnalysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
2 min readAnalysts downgraded several companies: Foghorn Therapeutics (FHTX) to Neutral, First Busey (BUSE) to Neutral with a $30 target, AST SpaceMobile (ASTS) to Neutral with a $65 target, AtriCure (ATRC) to Hold with a $57 target, and Equity Bancshares (EQBK) to Neutral with a $52 target. ASTS closed at $57.04 on Thursday.
2 min readFreedom Capital Markets downgraded AtriCure to Hold with a $57.00 price target, implying 6.4% upside. Concerns include overvaluation and uncertainty in clinical data, according to the analyst note.
1 min readFour biotech stocks reached 52-week highs on September 23, 2026. Alpha Teknova (TKNO) hit $9.35, reporting Q2 revenue of $12.2M. Moderna (MRNA) reached $192.31 after positive clinical trial data. AtriCure (ATRC) hit $65.48 with Q2 revenue of $153.6M. Illumina (ILMN) climbed to $256.17, reporting Q2 revenue of $1.59B.
2 min readAtriCure (NASDAQ:ATRC) Board Member Regina E Groves sold 5,313 shares for $288,070 on September 14, according to an SEC filing. ATRC shares were down 0.97% at $55.79 on Tuesday. The company reported 12.83% revenue growth and a 77.23% gross margin as of June 30, 2026, but has a high P/E ratio of 265.67 and an EPS of 0.18.
1 min readGROVES REGINA E sold 5,313 shares of AtriCure, Inc. (ATRC) at $54.22 ($0.29M total) on 2026-09-11.
1 min readAtriCure CTO Salvatore Privitera sold 3,657 shares at $55.0 each, totaling $201,135. The sale was part of a 10b5-1 plan. AtriCure (ATRC) stock is near its 52-week high, up 51% in a year. The company reported strong Q2 2026 earnings, beating estimates, but stock fell on cautious outlook. Analysts raised price targets, citing positive catalysts.
1 min readSeveral biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.
2 min read
